Drugs / BR9006-1
last change Aug 2020 re-read 3 minutes ago

BR9006-1

Investigated by
Boryung Pharmaceutical Co., Ltd

Trials 1

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04485585 Jul → Aug 2020 benign prostatic hyperplasia, overactive bladder Boryung Pharmaceutical Co., Ltd Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BR9006-1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04485585 ↗